Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions
By Christine Filippis / September 20, 2024
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar...
Read More
Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment
By Christine Filippis / August 8, 2024
Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating...
Read More
Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy
By Christine Filippis / July 25, 2024
Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics’ iPSC cell line. Cartherics, The University of...
Read More
